https://hipa.ai/drug/itepekimab/updates/trial-results-posted-nct04701983-2026-10-15 Hipa.ai en 2026-10-15T00:00:00.000Z Itepekimab Shows Lower COPD Exacerbation Rates in Phase 3 https://hipa.ai/drug/pembrolizumab/updates/trial-results-posted-nct05617313-2026-10-14 Hipa.ai en 2026-10-14T00:00:00.000Z Pembrolizumab NSCLC combination trial posts results with one response https://hipa.ai/drug/atezolizumab/updates/trial-results-posted-nct05715281-2026-10-14 Hipa.ai en 2026-10-14T00:00:00.000Z Atezolizumab Combination Reports 3.48-Month PFS in Rare Cancers https://hipa.ai/drug/nivolumab/updates/trial-results-posted-nct05337137-2026-10-14 Hipa.ai en 2026-10-14T00:00:00.000Z Nivolumab triplet shows lower response rate in liver cancer